Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Global Gaming League's founder Clinton Sparks and chairman Jeff Hoffman on their mission to bridge competitive eSports with mainstream celebrity culture.
AEVEX CEO Roger Wells joins to discuss the company's IPO and what it means for the future of autonomous defense systems in an era of rapid military innovation.
What does AI actually mean for the US economy? Andrew Husby of BNP Paribas breaks down the macro signals, risks, and opportunities hiding in plain sight.
Dominick Passanante of Panasonic Connect breaks down the innovations behind TOUGHBOOK and why rugged tech is more relevant than ever in today's mobile workforce
Voya Financial CEO Heather Lavallee marks 10 years of Voya Cares, spotlighting research and expanding financial access for Americans with disabilities.
When Treasury Secretary Scott Bessent (above) and Fed chair Jay Powell jointly summon America’s top bankers to a meeting in Washington, you know it’s big.
Kim Crawford Goodman, CEO of Smarsh, breaks down how financial firms are scaling AI while managing compliance, risk, and regulation in a changing landscape.
